Post by Deleted on Jun 25, 2017 15:19:20 GMT
We expect a focus on commercial preparation for binimetinib launch
following positive NEMO study
NRAS Melanoma – PDUFA date set for June 30, 2017; ODAC 1H17
We expect reiteration of key 2017 events across all programs
Binimetinib + encorafenib in BRAF Melanoma – NDA/MAA
submission expected 2017; Columbus Part 2 study evaluating
lower dose of Encorafenib is expected mid-2017
Encorafenib, binimetinib+cetuximab in BRAF CRC – Results from
triplet safety lead-in from phase 3 is expected in 2017;
Enrollment into phase 3 is expected to complete in 2018
ARRY-382 in Melanoma and NSCLC – Dose escalation data from
phase 1b in combination with Keytruda are expected in 2017
ARRY-797 in LMNA-related DCM – Phase 3 registration trial is
expected to begin in 2017
Selumetinib – (1) Thyroid Cancer – Top line results from the
phase 3 is expected in 2017; (2) NF1 – Top line results from a
registration trial is expected in 2017
*FY ending 30-Jun; cash balance does not include $123.9M raise in 4Q
=============================
C L